Early and Sustained Improvements in Sense of Smell with Tezepelumab Treatment in Patients with CRSwNP (WAYPOINT)

In WAYPOINT, tezepelumab produced early and sustained improvements in patient-reported and objective smell outcomes compared with placebo, and markedly reduced the proportion of patients with UPSIT-defined anosmia.